ARPO Aerpio Pharmaceuticals Inc

DGAP-News: Vara Research GmbH: QIAGEN Q4 2018 Consensus Estimates

DGAP-News: Vara Research GmbH / Key word(s): Miscellaneous
Vara Research GmbH: QIAGEN Q4 2018 Consensus Estimates

29.01.2019 / 10:06
The issuer is solely responsible for the content of this announcement.


​The calculated consensus for QIAGEN is based on the estimates of 17 major banks consulted by Vara Research.
 
All consensus numbers are quoted in $ millions.
 
Consensus estimates (average)              Q4 2018      Full Year 2018
Adjusted net sales                                        411,8                   1510.6
Growth rate (actual) in %                              3.7                        6.4
Growth rate at CER in %                                  6.7                         6.4
FX effect in percentage points                      -3.3                        -0.1
Adjusted operating income                           121.9                   405.7
Adjusted tax rate in %                                     20.0                       19.7
Adjusted diluted EPS ($/share)(1)                  0.40                       1.33
 
Please note that the consensus is also available on the QIAGEN corporate website:
 
/investor-relations/Analysts/consensus
 
Notes:
 
CER = Constant exchange rate
 
 
(1) Adjusted results are non-GAAP financial measures that QIAGEN believes
should be considered in addition to the reported results prepared in
accordance with generally accepted accounting principles, but should not be
considered a substitute. QIAGEN believes certain items - such as those
listed above - should be excluded from adjusted results when they are
outside the ongoing core operations, vary significantly from period to
period, or affect the comparability of results with its competitors and its
own prior periods. Includes non-GAAP sales related to the bioinformatics
acquisitions.
 
Dislaimer:
This document has been issued by Vara Research GmbH for information purposes only and is not intended to
constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings
and business developments of the relevant company. Such estimates and forecasts cannot be independently verified
by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not
responsible or liable as to its accuracy and completeness.


29.01.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


770249  29.01.2019 

fncls.ssp?fn=show_t_gif&application_id=770249&application_name=news&site_id=research_pool
EN
29/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch